EANM launches award for prostate cancer research
The European Association of Nuclear Medicine (EANM) has launched an award for research in prostate cancer treatment.
The 2026 EANM Young Scientist Network Award, aiming to accelerate innovation in alpha radioligand therapy in prostate cancer, offers three prizes of €40,000 (Platinum), €20,000 (Gold) and €10,000 (Silver).
EANM has opened up applications from early career researchers — PhD candidates, postdoctoral fellows, junior faculty, and clinicians-in-training — who are within 10 years of their terminal degree and affiliated with an institution in an EANM member country.
“Alpha radioligand therapy is rapidly emerging as a transformative frontier in precision oncology, and we strongly believe in the talent of researchers at the beginning of their careers in this field,” says EANM President Paola Anna Erba.
“This award was designed to nurture their growth by pairing research excellence with structured training, mentorship, and collaborative networking opportunities.”
The deadline for applications is 18 May 2026, with winners set to be announced at the EANM’26 Congress later this year.
